The Type 1 Diabetes TrialNet Consortium was initiated in 2001 following completion of its predecessor, the Diabetes Prevention Trial-Type 1 (DPT-1). This network consists of 14 US and 4 international clinical sites. In addition, there are more than 200 US affiliate sites which perform subject screening, a Central Coordinating Center, and several TrialNet-associated laboratories. The goals of the TrialNet consortium are to prevent or delay the onset of T1D, to test interventions aimed at decreasing beta cell destruction and/or enhancing beta cell survival in persons with T1D with residual beta cell function, and the performance of mechanistic studies. The University of Minnesota (UMN) has been a DPT-1/TrialNet Clinical Center since the beginning. Throughout this history, UMN has been highly productive and engaged, contributing intellectually to project development and reporting, and actively participating in all aspects of each TrialNet project.
The aims of this renewal grant are to continue the tradition of UMN as a high-quality, high-performing TrialNet Clinical Center in the critical areas of project development, screening, recruitment, treatment, follow-up, and reporting;to increase screening rates for detection of subjects at high risk for development of T1D by further developing and supporting UMN affiliates and by exploring general population screening within new UMN research facilities at the Minnesota State Fair;and to foster collaborations with new T1D researchers in the Upper Midwest region.

Public Health Relevance

Type 1 diabetes imposes a tremendous burden on individuals, families, and society. Preventing or delaying the onset of T1D, the primary focus of TrialNet, would reduce costs to society and the suffering of affected individuals and their family.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project--Cooperative Agreements (U01)
Project #
2U01DK085476-06
Application #
8774732
Study Section
Special Emphasis Panel (ZDK1-GRB-J (M2))
Program Officer
Leschek, Ellen W
Project Start
2009-09-30
Project End
2019-04-30
Budget Start
2014-08-01
Budget End
2015-04-30
Support Year
6
Fiscal Year
2014
Total Cost
$753,507
Indirect Cost
$257,779
Name
University of Minnesota Twin Cities
Department
Pediatrics
Type
Schools of Medicine
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Narsale, Aditi; Moya, Rosita; Robertson, Hannah Kathryn et al. (2016) Data on correlations between T cell subset frequencies and length of partial remission in type 1 diabetes. Data Brief 8:1348-51
Bundy, Brian N; Krischer, Jeffrey P; Type 1 Diabetes TrialNet Study Group (2016) A model-based approach to sample size estimation in recent onset type 1 diabetes. Diabetes Metab Res Rev 32:827-834
Pugliese, Alberto; Boulware, David; Yu, Liping et al. (2016) HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease Progression. Diabetes 65:1109-19
Hao, Wei; Gitelman, Steven; DiMeglio, Linda A et al. (2016) Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose. Diabetes Care 39:1664-70
DiMeglio, Linda A; Cheng, Peiyao; Beck, Roy W et al. (2016) Changes in beta cell function during the proximate post-diagnosis period in persons with type 1 diabetes. Pediatr Diabetes 17:237-43
Moya, Rosita; Robertson, Hannah Kathryn; Payne, Dawson et al. (2016) A pilot study showing associations between frequency of CD4(+) memory cell subsets at diagnosis and duration of partial remission in type 1 diabetes. Clin Immunol 166-167:72-80
Sims, Emily K; Chaudhry, Zunaira; Watkins, Renecia et al. (2016) Elevations in the Fasting Serum Proinsulin-to-C-Peptide Ratio Precede the Onset of Type 1 Diabetes. Diabetes Care 39:1519-26
Sosenko, Jay M (2016) Staging the progression to type 1 diabetes with prediagnostic markers. Curr Opin Endocrinol Diabetes Obes 23:297-305
Meah, Farah A; DiMeglio, Linda A; Greenbaum, Carla J et al. (2016) The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants. Diabetologia 59:1186-95
Xu, Ping; Krischer, Jeffrey P; Type 1 Diabetes TrialNet Study Group (2016) Prognostic Classification Factors Associated With Development of Multiple Autoantibodies, Dysglycemia, and Type 1 Diabetes-A Recursive Partitioning Analysis. Diabetes Care 39:1036-44

Showing the most recent 10 out of 35 publications